In collaboration between NCITA and the ReIMAGINE consortium, the PROMIS Study Dataset has been made openly and freely available to the scientific community for non-commercial, non-profit use, in the hope of facilitating future advancement and discovery in prostate cancer diagnosis and treatment.
The “PROMIS – Prostate MRI Imaging Study – Evaluation of multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer” study was a prospective, multi-centre, paired-cohort, confirmatory study that tested the value of Multi Parametric Magnetic Resonance Imaging (MP-MRI) for men with a suspicion of prostate cancer who had been recommended to have a prostate biopsy. Participants in the study underwent both a template prostate mapping (TPM) biopsy and a Trans-rectal Ultrasound (TRUS) biopsy as a combined procedure after MRI, regardless of MRI outcome (A 5-point Likert radiology reporting scale was used). The PROMIS results were published in the Lancet in January 2017, and demonstrated:
1. TRUS is a poor test for the diagnosis of clinically significant prostate cancer. The sensitivity was only 48% and thus missed over half the cases.
2. mp-MRI is a highly sensitive test (93%) for the detection of clinically significant cancer and if performed prior to the biopsy, it can identify about 25% of men who might safely avoid a biopsy.
3. A subsequent cost effectiveness analysis demonstrated that performing an mp-MRI scan prior to biopsy was highly cost effective.
PROMIS was funded by the UK Government Department of Health, National Institute of Health Research–Health Technology Assessment Programme, (Project number 09/22/67). Support was also provided by National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre, National Institute for Health Research (NIHR) The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and National Institute for Health Research (NIHR) Imperial Biomedical Research Centre.
The original PROMIS study was coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL and sponsored by UCL. The PROMIS Biobank was funded by Prostate Cancer UK (PG10-17). The PROMIS dataset and the biobank is under the research governance of the ReIMAGINE Risk Trial Management Group (funded by Medical Research Council (UKRI) and Cancer Research UK: MR/R014043/1), in collaboration with the National Cancer Imaging Translational Accelerator (NCITA, funded by a Cancer Research UK Accelerator Award C42780/A27066).
Queries regarding this dataset can be addressed to reimagine@ucl.ac.uk or ncita.general@ucl.ac.uk
With thanks to the following people for helping make PROMIS open access:
Dr Tom Syer, Ms Jude Holmes, Miss Julia Markus, Dr Yaozhi Lu, Ms Sumandeep Kaur, Mrs Rosie Clow, Dr Aida Santaolalla
Data Use Agreement
The PROMIS study dataset is distributed to the greater scientific community under the following terms:
1. You will not make any attempts to identify or make contact with any of the human participants, or use the PROMIS study dataset in a manner which could allow or facilitate human participants to be identified. This includes but is not limited to any attempts to link this dataset to any other information which may be available to you.
2. You will acknowledge the use of the PROMIS study dataset and data derived from the PROMIS study dataset whenever publishing, presenting or otherwise disseminating any results or algorithms that benefitted from their use. Papers, book chapters, books, posters, oral presentations, and all other printed and digital presentations of results derived from the PROMIS study dataset must contain the following acknowledgement:
“The data used in the analysis for this manuscript were provided from the PROMIS study, led by University College London (UCL). PROMIS was funded by the UK Government Department of Health, National Institute of Health Research–Health Technology Assessment Programme, (Project number 09/22/67). Support was also provided by National Institute for Health Research (NIHR) UCLH/UCL Biomedical Research Centre, National Institute for Health Research (NIHR) The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and National Institute for Health Research (NIHR) Imperial Biomedical Research Centre. The original PROMIS study was coordinated by the Medical Research Council Clinical Trials Unit (MRC CTU) at UCL and sponsored by UCL. The PROMIS Biobank was funded by Prostate Cancer UK (PG10-17). The PROMIS dataset and the biobank is under the research governance of the ReIMAGINE Risk Trial Management Group (funded by Medical Research Council (UKRI) and Cancer Research UK: MR/R014043/1).”
3. You agree to provide University College London upon request with information on your use of the PROMIS study dataset.
4. You will only use the PROMIS study dataset for non-commercial, non-profit purposes only.
5. Failure to abide by these data use terms may result in termination of your right to access and use the PROMIS study dataset and/or further legal remedies.
6. These data use terms and your use of the PROMIS study dataset is governed by English law & the exclusive jurisdiction of the English courts.
What data is available?
575 participant’s mpMRI DICOMs files (.dcm)
575 MRI study report forms (PDF)
575 TPM study report forms (PDF)
22 study database download spreadsheets (.xlsx)
By submitting a data request, I am agreeing to abide by the terms of the PROMIS data use Agreement